Orexigen Therapeutics announced that CEO and President Gary Tollefson, M.D., Ph.D., is taking a leave of absence from the Company, but will remain a member of the Board of Directors. The Company's current non-executive Chairman of the Board, Eckard Weber, M.D. has been appointed Executive Chairman and interim Chief Executive Officer.
Targeted Genetics' Board of Directors has elected B.G. Susan Robinson as President and CEO.
Alexion Pharmaceuticals co-founder and COO David W. Keiser will retire this year, but will remain on the Board until his term is up in 2009.
William N. Garbarini, Jr. has been promoted from Executive Director, Orthopaedics Business Unit to the Vice President of the new Orthopaedics and Urology Business Unit at Ferring Pharmaceuticals.
James Albrecht, Jr., Chief Financial Officer of Introgen Therapeutics has resigned.
Maccine announced the appointment of Leigh Berryman to CEO.
John J. Young, MD has been appointed Chief Medical Officer of Accumetrics.
Cynvec announced today the appointment of Frank D. Stonebanks as President and Chief Executive Officer. In addition to his role as CEO, Mr. Stonebanks will serve on Cynvec's Board of Directors.
Potentia Pharmaceuticals announced the appointments of Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to its Scientific Advisory Board.
Regado Biosciences announced the appointment of Alexander R. Giaquinto, Ph.D., to the newly created position of Senior Vice President of Regulatory Affairs and Quality Assurance.
Kendle has reappointed Timothy M. Mooney to the Company's Board of Directors.
Encorium Group has appointed Wall Street veteran Shahab Fatheazam to its Board of Directors.
Cardiologist Ethan Weiss, M.D. has been appointed to Bionovo's Scientific Advisory Board.